Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04860713 · ClinicalTrials.gov registry record · Phase 4
An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache
A Phase 4 study, sponsored by Antonios Likourezos.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT04860713 is a Phase 4 study that has completed, run by Antonios Likourezos. The registered enrollment target is 5 participants.
The verdict
NCT04860713, a Phase 4 study, has completed, sponsored by Antonios Likourezos.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Headaches affect over 50% of patients annually, with close to 4% of ED visits for headache. Most headaches managed in the ED are benign, with 90% of these headaches classified as tension, migraine, or cluster. At present, the satisfaction with ED treatment of headache is low, and despite the multitude of available medications, the evidence- based treatment options are often quite limited. There are over twenty different types of medications available to the ED clinicians for managing headache, many with different routes of administration (parenteral, intranasal, subcutaneous, and oral). Many of these medications are provided in so-called "headache cocktail", which varies based on the physician, institution, and patient preferences.
Interventions
- DRUG aspirin and ketamine
- DRUG Nurtec (Rimegepant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04860713
The ClinicalTrials.gov registry entry for NCT04860713 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antonios Likourezos, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aspirin and ketamine is the first listed.
NCT04860713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04860713 about?
NCT04860713 is a clinical study titled "An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache". Headaches affect over 50% of patients annually, with close to 4% of ED visits for headache. Most headaches managed in the ED are benign, with 90% of these headaches classified as tension, migraine, or cluster. At present, the satisfaction with ED treatment of headache is low, and despite the multitu...
What is the current status of trial NCT04860713?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2021-04-22. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT04860713?
The interventions under investigation include: aspirin and ketamine (DRUG), Nurtec (Rimegepant) (DRUG).
Who is sponsoring clinical trial NCT04860713?
This trial is sponsored by Antonios Likourezos, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.